Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating MT-4561, an investigational drug, in adults with various advanced solid tumors including head and neck, lung, esophageal, gastric, biliary tract, pancreatic, breast, ovarian, cervical, endometrial, prostate, urothelial, neuroendocrine tumors, soft tissue sarcoma, and NUT carcinoma. This Phase III study aims to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and effectiveness of MT-4561 in patients who have exhausted other treatment options or cannot tolerate standard therapies. The study is sponsored by Tanabe Pharma America, Inc. The study is conducted in three parts. Part 1 focuses on finding the maximum tolerated dose using a dose-escalation design with weekly intravenous infusions of MT-4561 in 28-day cycles until disease progression or stopping criteria are met. Parts 2 and 3 will explore dose optimization and drug interactions after reviewing Part 1 results. Participants receive the study drug via intravenous infusion once a week during each 28-day cycle. Participants will be regularly monitored for side effects, dose-limiting toxicities, and drug levels in blood. Researchers will assess tumor response and disease control over approximately three years. Evaluations include physical exams, lab tests, and imaging to measure tumor changes, survival, and duration of disease stability. The study includes screening, treatment cycles, and follow-up visits to track safety and outcomes throughout the trial period.
Actively Recruiting
Researchers are conducting an observational study to understand the safety and effectiveness of darolutamide combined with androgen deprivation therapy ADT and docetaxel in Japanese men with low-volume metastatic hormone-sensitive prostate cancer mHSPC. This cancer involves the prostate gland spreading to three or fewer bones without affecting organs like the lungs and liver, and it responds to hormone therapy. The study focuses on collecting and analyzing medical records from routine clinical care without altering treatment plans. Participants will receive darolutamide, ADT, and docetaxel as prescribed by their doctors during usual care. Darolutamide blocks androgen signals to slow cancer growth, ADT lowers testosterone levels, and docetaxel is chemotherapy that stops cancer cell growth. The study observes how this combination therapy works in real-world settings without giving treatment advice or modifications as part of the study. Participants health records will be reviewed for up to several years, with data collected between October 2024 and June 2031. Researchers will monitor prostate-specific antigen PSA levels after 12 months to assess response, and track any adverse events, serious adverse events, or special interest adverse events that affect treatment continuation or dosage. No extra visits are required all information comes from routine medical care visits and records.
Actively Recruiting
This observational study focuses on Japanese people with chronic heart failure who are receiving the drug vericiguat. Chronic heart failure is a long-term condition where the heart does not pump blood effectively, which can lead to serious health issues, hospitalization, or death. Researchers aim to learn more about the safety of vericiguat in a broader Japanese population and during prolonged treatment, especially since limited patients have received this drug so far. Participants include those who will start vericiguat therapy alongside standard treatment and those continuing standard care without vericiguat. The dosing of vericiguat is determined by the treating physician based on approved product information. The study collects data from medical records and electronic forms during routine medical visits over a period of up to two years. It compares the safety and cardiovascular outcomes, such as death from heart-related causes, between those treated with vericiguat and those receiving standard care. During the study, researchers will document participants medical history, treatments, laboratory results, vital signs, cardiac exam results, hospitalizations related to heart failure, and any adverse events experienced. The studys main focus is on the severity, seriousness, outcome, and causes of adverse events related to vericiguat treatment. The total study duration, including data analysis, is six years, allowing for long-term safety monitoring and evaluation of treatment effects.
Actively Recruiting
Researchers are studying the effects of duvakitug in adults and older teenagers with moderately to severely active Ulcerative Colitis UC, a condition causing inflammation in the colon. This Phase 3 clinical trial is designed to evaluate both the effectiveness and safety of this treatment compared to placebo injections. The study is randomized, double-blind, and takes place at multiple international centers to ensure reliable results. Participants receive subcutaneous injections of either one of two doses of duvakitug or a placebo according to the study protocol. The trial includes a screening period followed by a 12-week initial treatment phase, with an additional 12-week extended induction period for those who do not respond initially. Participants who do not join the maintenance study will have a 45-day follow-up visit after completing the induction phases. During the study, participants will attend up to 8 visits in the initial treatment phases and up to 15 visits if they continue to the extended induction period. Researchers will assess clinical remission rates, endoscopic improvement, symptom responses, quality of life scores, and safety outcomes such as adverse events and immune responses to the drug. The total study participation may last up to 35 weeks, allowing close monitoring of health and treatment effects throughout.
Actively Recruiting
Researchers are studying people in Asia and the United States who have chronic kidney disease CKD along with type 2 diabetes T2D to understand more about the use, safety, and effectiveness of the treatment finerenone in real-world settings. CKD is a long-term condition where the kidneys progressively lose function, and T2D is a condition where the body does not produce or use insulin properly, leading to high blood sugar that can damage the kidneys. Finerenone blocks certain proteins called mineralocorticoid receptors, which may help protect the kidneys, heart, and blood vessels. It was recently approved for use in the US, and this observational study aims to collect information on people receiving finerenone as part of their regular care. The study uses data from commercial electronic health records and national claims databases in Asia and the US, covering the period from July 1, 2021, to the most recent available data. Participants are adults with CKD and T2D who have started finerenone treatment prescribed by their doctors. Since this is an observational study, no new treatments or interventions are given by the researchers. Instead, the study collects existing data on participants, including their kidney function, heart health, other medical conditions, and medications used while on finerenone. Participants are not required to attend any study visits or tests specifically for this research. The researchers use already available health records to analyze participant characteristics, comorbidities, and medication use before and after starting finerenone. They also monitor outcomes such as kidney failure, cardiovascular events, and medication dosing over time. The study will continue until September 30, 2026, gathering long-term real-world information about finerenone use and safety in people with CKD and T2D.
Actively Recruiting
Researchers are observing children aged 7 to under 12 years with mild, moderate, or severe hemophilia A who are receiving damoctocog alfa pegol. This study aims to learn more about how this treatment works in preventing bleeding episodes during routine medical care. Participants have previously been treated with damoctocog alfa pegol or other factor VIII products, and the study focuses on their usual treatment without any changes or advice from the study team. Participants receive damoctocog alfa pegol as prescribed by their own doctors for regular continuous prophylaxis to prevent bleeding. The study collects data from routine medical care and does not require additional visits or tests. Historical medical records and interviews with patients and their guardians provide background information. Guardians also keep a health diary to record bleeding episodes and treatment, and complete questionnaires assessing the impact of hemophilia on daily life. Data collection occurs over two years or until participants leave the study or change treatment. Researchers track the number and type of bleeding episodes, treatment details including dosing and infusions, and overall health status. The main outcome measures include the number of treated bleeds documented in diaries. No extra procedures are needed beyond routine care, and the study monitors how damoctocog alfa pegol is used in real-world settings.
Actively Recruiting
Researchers are studying larotrectinib as a treatment for people of all ages with advanced or recurring TRK fusion cancer, a type of cancer caused by a specific gene fusion that leads to cancer cell growth. This research aims to gather real-world information about how larotrectinib affects patients when used as part of their regular medical care. Participants receive larotrectinib prescribed by their doctors according to usual clinical practice. The study does not require extra visits or tests beyond what patients normally have during their treatment. Researchers will collect data from medical records, interviews with patients or their guardians, and regular doctor visits. The study includes various cancer types such as gastrointestinal, head and neck, lung, soft tissue sarcoma, central nervous system, and melanoma. During the study, researchers will monitor patients for up to about 2 years for adults and 8 years for children. They will track treatment-related side effects, their severity, frequency, seriousness, and outcomes, as well as assess how the cancer responds to larotrectinib. Information like neurological exams, growth changes in children, and overall survival will also be collected to better understand the long-term effects and safety of larotrectinib in routine care.
Actively Recruiting
This research aims to evaluate the long-term safety and effectiveness of avacopan in Japanese patients diagnosed with microscopic polyangiitis or granulomatosis with polyangiitis. These conditions involve inflammation of blood vessels and the study focuses on real-world use of the medication. The survey is observational and tracks patients over time to gather important information on treatment outcomes. Participants receive avacopan through oral administration as part of their treatment. The study observes patients who are already being treated with avacopan to assess its impact under normal usage conditions. There are no comparison groups or placebo treatments, as this is a drug use-results survey. During the study, researchers monitor adverse events and overall patient safety for up to two years. Data collection includes recording any side effects or health changes related to avacopan. The goal is to better understand the medications safety profile during long-term use in this patient population. Participants remain under their usual medical care throughout the survey.
Actively Recruiting
Researchers are studying the effects of secutrelvir compared to a placebo in people aged 12 to 74 who have COVID-19 but are not hospitalized. The study focuses on how quickly clinical symptoms resolve when starting treatment within 48 hours of symptom onset. This Phase 3 study aims to understand the treatments safety and effectiveness in relieving COVID-19 symptoms. Participants will be randomly assigned to receive either secutrelvir or a placebo, both given as oral tablets. The study uses a double-blind design, meaning neither participants nor researchers know who receives the active drug or placebo. Treatment begins promptly within 48 hours of symptom start, and participants are monitored throughout the study period. During the study, participants will be regularly assessed for the resolution and alleviation of 14 specific COVID-19 symptoms, fever reduction, and viral levels in the body. Safety is monitored by tracking any treatment-emergent adverse events. The primary outcome measure is the time to first resolution of symptoms within 21 days. The study lasts until primary completion around July 2027 with follow-up assessments continuing through 28 days after treatment begins.
Actively Recruiting
Researchers are conducting a prospective, observational, multi-center study to assess the safety and effectiveness of Eylea Aflibercept injection in patients diagnosed with Neovascular Glaucoma in Japan. This study focuses on patients for whom the decision to use Eylea has already been made by their doctors in routine clinical practice. The goal is to collect real-world data on how patients respond to this treatment over time. Participants receive Eylea through intravitreal injection as part of their usual care, with the treatment decision guided by the Japanese package insert. The study does not assign treatments but observes patients who have been prescribed Eylea. Patients are followed for up to six months from the start of their Eylea treatment or until they can no longer be followed, such as if they are lost to follow-up. During the study, data are collected at initial, follow-up, and final visits, aligned with routine medical appointments. Researchers assess safety by recording any adverse events and monitor effectiveness by measuring intraocular pressure, visual acuity changes, and improvements in anterior neovascularization. In total, 480 patients will be included, providing valuable information about Eyleas use in everyday clinical settings.